. Introduction

Judicial review of trait manipulation cases concerns the power of courts to examine the legality, constitutionality, fairness, and scientific justification of decisions involving the alteration, selection, suppression, or enhancement of human, animal, or plant traits.

Trait manipulation may involve conventional breeding, genetic engineering, gene editing, embryo selection, or technologies intended to influence physical, behavioral, cognitive, or disease-related characteristics.

The central legal question is:

When does the manipulation of biological traits become a legitimate scientific or medical activity, and when does it violate fundamental rights, equality, human dignity, environmental protections, or statutory safeguards?

There is no single universal legal doctrine specifically called “judicial review of trait manipulation.” Instead, courts apply constitutional law, administrative law, medical law, biotechnology regulations, intellectual property law, and environmental law, depending on the facts.

2. Meaning and scope of trait manipulation

Harnessing CRISPR: A Comprehensive Guide for Future Physi...

A. Genetic trait manipulation

Altering genetic sequences to change a biological characteristic, potentially including disease susceptibility, inherited disorders, or plant resistance. Gene editing raises questions about safety, consent, heritable effects, and regulatory authorization.

Best IVF Center in Lahore | IVF Cost in Pakistan 2026 | Dr. Adnan

B. Embryo selection and reproductive choices

Selecting embryos based on genetic characteristics, including disease-associated variants or other traits. Relevant issues include reproductive autonomy, disability discrimination, privacy, and the legal status of embryos.

Female Scientist In Greenhouse Researching Tomato Crop. GMO plants

C. Agricultural and animal trait manipulation

Developing crops or animals with traits such as pest resistance, altered growth, or disease resistance. Courts may examine biosafety approvals, environmental impacts, patent rights, and effects on farmers.

ZagrebMed - Decoding Your DNA: The Rise of Personalized Medicine

D. Non-heritable or somatic interventions

Modifying cells in an existing person, for example through gene therapy. Legal scrutiny may focus on informed consent, clinical-trial authorization, medical negligence, product safety, and long-term monitoring.

A crucial distinction is that treating a serious disease is not legally equivalent to enhancing a non-medical characteristic. The applicable rules depend on the intervention, its purpose, its risks, and the jurisdiction.

3. Leading case laws on trait manipulation

Case 1: Gene Campaign v. Union of India (2024)

Supreme Court of India · 2024 INSC 545 · Decided 23 July 2024

Facts: The case concerned the regulatory approval granted for the environmental release of genetically modified mustard hybrid DMH-11. The petitioners challenged the approval on grounds including biosafety assessment, the precautionary principle, environmental protection, and procedural legality.

Legal issues:

Whether regulatory decisions concerning genetically modified crops are subject to judicial review.

Whether the environmental approval complied with statutory requirements and constitutional environmental protections.

Whether the decision adequately considered scientific uncertainty, potential ecological risks, and expert recommendations.

Judgment: The two judges disagreed on the validity of the approval. Justice B. V. Nagarathna considered the approval legally defective, particularly because the assessment had not adequately determined the risks associated with herbicide tolerance and other biosafety concerns. Justice Sanjay Karol took a different view of the regulatory decision and the scope of judicial intervention in technical and policy matters. The divided opinions meant there was no single majority ruling resolving every disputed issue.

The Court agreed that judicial review of decisions concerning genetically modified organisms is permissible. It also directed the government to develop a national policy on GM crops through consultation with relevant experts, farmers, state governments, and other stakeholders.

LegalRes+1

Legal principle: Scientific expertise does not immunize regulatory decisions from judicial scrutiny. Courts may examine whether the authority followed the law, considered relevant evidence, and adequately addressed environmental risks.

Relevance to trait manipulation: This is a particularly important Indian precedent for challenges involving engineered plant traits, environmental release, biosafety approvals, and regulatory accountability.

Case 2: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

569 U.S. 576 (2013) · United States Supreme Court

Facts: Myriad Genetics identified the location and sequence of the BRCA1 and BRCA2 genes, variants of which can increase the risk of breast and ovarian cancer. The company obtained patents relating to these genes, leading to a legal challenge by medical organizations, researchers, and patients.

Issue: Can a naturally occurring human gene become patentable merely because scientists isolate it from the body?

Judgment: The US Supreme Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated. However, complementary DNA (cDNA), which is created by removing introns from a DNA sequence, may be patent-eligible because it is not naturally occurring in the same form.

LII / Legal Information Institute+1

Legal principle: Discovering a naturally occurring genetic trait is legally different from creating a patent-eligible invention.

Relevance: This case helps courts distinguish between biological discoveries, genetic modifications, and human-made inventions. It does not prohibit genetic research or establish a general ban on manipulating traits.

Case 3: Diamond v. Chakrabarty (1980)

447 U.S. 303 (1980) · United States Supreme Court

Facts: An inventor developed a genetically modified bacterium capable of breaking down components of crude oil. The patent dispute concerned whether a living, human-engineered organism could qualify as patentable subject matter.

Issue: Can a genetically modified living organism be patented?

Judgment: The Court held that the modified bacterium was patent-eligible subject matter because it was a human-made invention with markedly different characteristics and capabilities from naturally occurring organisms.

Legal principle: Under the applicable US patent law, a sufficiently engineered organism may be patentable, unlike a discovery of a naturally occurring organism as such.

LII / Legal Information Institute+1

Relevance: The decision provides a foundational distinction between naturally occurring traits and engineered biological characteristics. Patent eligibility, however, does not automatically establish that an organism is safe to release into the environment or that its use is lawful under other regulations.

Case 4: Monsanto Canada Inc. v. Schmeiser (2004)

2004 SCC 34 · Supreme Court of Canada

Facts: Monsanto held a patent relating to a genetically engineered canola trait conferring resistance to glyphosate herbicide. Percy Schmeiser grew canola containing the patented trait, and the dispute concerned patent infringement and the use of the protected technology.

Issue: Can the unauthorized use of a patented genetic trait infringe patent rights even when the dispute involves a plant rather than a conventional manufactured product?

Judgment: The Supreme Court of Canada found patent infringement on the particular facts, but it did not award Monsanto damages or an accounting of profits because Schmeiser had not commercially benefited from the patented trait.

Legal principle: Patent rights may extend to the use of a patented genetic invention in living material, depending on the patent and the circumstances. The judgment did not establish that every presence of a patented gene automatically amounts to infringement.

Relevance: The case demonstrates how trait manipulation can create disputes over farmers' rights, seed ownership, biotechnology patents, and the commercial use of engineered traits.

Case 5: Nuziveedu Seeds Ltd. v. Monsanto Technology LLC (2019)

Supreme Court of India · (2019) 3 SCC 381

Facts: The dispute involved Monsanto's Bt cotton technology, licensing arrangements, and the relationship between patent law and India's plant-variety protection framework. The controversy included whether the relevant biotechnology invention could be protected under the Patents Act, 1970.

Issue: How should courts determine the relationship between biotechnology patents and statutory restrictions relating to plants, seeds, and plant varieties?

Decision: The Supreme Court set aside the Delhi High Court Division Bench judgment and remitted the matter for fresh consideration by the Single Judge. It did not finally resolve all substantive questions of patentability.

Legal principle: The legal protection of engineered biological traits depends on the precise invention, the statutory exclusions, the patent claims, and the applicable plant-variety legislation.

Relevance: This case is important in India for disputes involving genetically modified seeds, licensing of biological traits, agricultural innovation, and the limits of intellectual property rights.

4. Constitutional and statutory principles governing judicial review in India

In India, a challenge to trait manipulation may be brought before a High Court under Article 226 of the Constitution or, where the requirements are satisfied, before the Supreme Court under Article 32.

The following principles are particularly relevant.

These provisions do not automatically prohibit trait manipulation. The court must examine the particular technology, the applicable legislation, and the evidence.

5. Additional judicial precedents

A. K.S. Puttaswamy v. Union of India (2017)

2017 10 SCC 1 · Supreme Court of India

The Supreme Court recognized privacy as a fundamental right protected under Article 21 and other constitutional freedoms.

Application: Genetic testing, the collection of genomic information, and the selection or alteration of traits may raise questions about informational privacy, bodily autonomy, and consent. The case supplies constitutional principles for analyzing such questions; it did not decide the legality of gene editing itself.

B. Suchita Srivastava v. Chandigarh Administration (2009)

(2009) 9 SCC 1 · Supreme Court of India

The Court recognized reproductive choice as an aspect of personal liberty under Article 21.

Application: Decisions concerning reproductive interventions and genetic testing may implicate individual autonomy. However, reproductive autonomy does not automatically establish an unrestricted right to undertake heritable genome editing or to demand approval for every reproductive technology.

C. Indian Council for Enviro-Legal Action v. Union of India (1996)

(1996) 3 SCC 212 · Supreme Court of India

The Court reinforced the polluter-pays principle in environmental law.

Application: Where an industrial or biotechnology activity causes legally attributable environmental damage, questions of remediation and financial responsibility may arise. Liability depends on the applicable law and established facts; the principle is not a blanket rule imposing liability for every uncertain biological risk.

6. Grounds on which courts may review trait manipulation decisions

1. Illegality

A regulator authorizes a genetic intervention without the required statutory approval or exceeds its legal powers.

2. Procedural unfairness

The authority fails to follow mandatory procedures, disregards required consultations, or denies a legally required opportunity to respond.

3. Irrationality or non-application of mind

The decision ignores material evidence, relies on irrelevant considerations, or lacks a rational connection between the evidence and the conclusion.

4. Constitutional violations

The decision unjustifiably interferes with fundamental rights, discriminates unlawfully, or fails to meet applicable constitutional standards.

5. Inadequate assessment of environmental risk

A regulator fails to address material biosafety concerns, required environmental assessments, or legally applicable precautionary obligations.

Judicial review generally examines the legality of the decision-making process and the limits of public power. It is not ordinarily a fresh scientific trial in which judges replace qualified regulators on every technical question.

7. The precautionary principle and scientific uncertainty

Trait manipulation may involve uncertain long-term consequences, particularly where modified organisms can reproduce, spread, or interact with ecosystems.

Under Indian environmental jurisprudence, the precautionary principle can require preventive safeguards even where scientific certainty is incomplete. Its precise application depends on the applicable law, the evidence, the seriousness of potential harm, and the nature of the activity.

Courts may examine whether authorities have:

Identified plausible risks and sensitive ecological pathways.

Obtained reliable scientific evidence and independent expert advice.

Considered alternative technologies and less harmful approaches.

Established monitoring, containment, or post-release controls where required.

Explained their conclusions and addressed significant contrary evidence.

The Gene Campaign litigation is particularly instructive because the judicial disagreement over GM mustard illustrates the difficulty of distinguishing legitimate scientific discretion from legally inadequate risk assessment.

LegalRes+1

8. Remedies available to courts

Depending on the governing law and the facts, a court may:

Quash an approval that is unlawful or constitutionally defective.

Remit the matter for reconsideration by the competent authority.

Require further assessment or disclosure where legally necessary.

Order interim protection against an activity where the applicable legal test for interim relief is satisfied.

Require monitoring or corrective measures within the court's lawful remedial powers.

Award compensation or direct remediation where the relevant legal requirements are established.

Courts must tailor remedies to the violation. A procedural defect may justify reconsideration rather than a permanent prohibition on the underlying technology.

9. Hypothetical example

Suppose a biotechnology company develops a genetically modified crop designed to resist pests. The competent authority grants environmental approval, but farmers and environmental organizations allege that the assessment ignored risks to non-target insects and local biodiversity.

The judicial process could proceed as follows:

Regulatory approval

The authority authorizes the engineered crop.

Legal challenge

Petitioners allege inadequate risk assessment or procedural illegality.

Judicial scrutiny

The court examines statutory compliance, evidence, reasons, and applicable constitutional principles.

Appropriate remedy

The approval may be upheld, reconsidered, quashed, or made subject to lawful safeguards.

The court would not necessarily prohibit the crop simply because uncertainty exists. It would determine whether the relevant legal standards were met and whether the authority adequately addressed the material risks.

10. Critical analysis

Three competing interests shape judicial review in this area.

Scientific innovation: Excessive or arbitrary restrictions can impede research, medical treatment, agricultural productivity, and technological development.

Individual rights and equality: Trait manipulation can raise concerns about informed consent, genetic privacy, reproductive freedom, disability discrimination, and the possibility of coercive enhancement practices.

Public and environmental protection: Genetic interventions may create risks extending beyond the individual receiving treatment, particularly when they involve heritable changes or organisms released into the environment.

A sound judicial approach should neither presume that every new technology is dangerous nor assume that scientific progress excuses inadequate safeguards. Courts should enforce statutory requirements, protect fundamental rights, scrutinize conflicts of interest, and respect legitimate scientific expertise while ensuring that decisions remain legally accountable.

11. Conclusion

Judicial review of trait manipulation is an emerging, cross-disciplinary field rather than a single established cause of action. Its legal framework draws upon constitutional rights, administrative-law principles, biotechnology regulation, environmental law, medical ethics, and intellectual property law.

For India, the most directly relevant precedent among the cases discussed is Gene Campaign v. Union of India (2024), which confirms that decisions concerning genetically modified organisms are judicially reviewable while illustrating the complexities of reviewing scientific risk assessments. Nuziveedu Seeds addresses the separate but related question of intellectual property protection for engineered agricultural traits.

The central principle is that biological innovation must operate within the limits of law, and regulatory decisions affecting people, agriculture, or the environment must remain open to lawful judicial scrutiny.

Academic note: The authorities above address different aspects of trait manipulation. They should not be cited as though they collectively establish a general legal prohibition on genetic engineering or a universal right to alter human traits. The outcome of any actual case depends on the jurisdiction, technology, statutory framework, and evidence.